Fig. 7: Schematic depiction and molecular mechanisms of early rapid clinical progression of patients with BPH.

The CYP19/estrogen/GPER/Gαi pathway triggers the early rapid clinical progression of patients with BPH by promoting prostatic fibrosis and prostatic stromal cell proliferation.